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Abstract
Exercise provides a cornerstone in the prevention and treatment of several chronic diseases. The use of in vivo exercise models
alone cannot fully establish the skeletal muscle-specific mechanisms involved in such health-promoting effects. As such, models
that replicate exercise-like effects in vitro provide useful tools to allow investigations that are not otherwise possible in vivo. In
this review, we provide an overview of experimental models currently used to induce exercise-like effects in skeletal muscle
in vitro. In particular, the appropriateness of electrical pulse stimulation and several pharmacological compounds to resemble
exercise, as well as important technical considerations, are addressed. Each model covered herein provides a useful tool to
investigate different aspects of exercise with a level of abstraction not possible in vivo. That said, none of these models are perfect
under all circumstances, and the choice of model (and terminology) used should be informed by the specific research question
whilst accounting for the several inherent limitations of each model. Further work is required to develop and optimise the current
experimental models used, such as combination with complementary techniques during treatment, and thereby improve their
overall utility and impact within muscle biology research.
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Introduction
Vast evidence supports the role of physical activity and exer-
cise in the prevention and treatment of many chronic diseases,
such as cardiovascular disease and type 2 diabetes mellitus
(T2DM) [20, 97]. Despite extensive research efforts, the exact
underlying mechanisms responsible for these benefits remain
to be determined. That said, skeletal muscle contraction per se
likely contributes to some or many of the exercise-mediated
health benefits, be that through direct effects within the
contracting skeletal muscle cells (such as improved glucose
uptake and insulin sensitivity [74, 102]) or via cross-talk with
other organs mediated by factors liberated from the skeletal
muscle (e.g. myokines, metabolites, microRNAs, exosomes)
[95, 96]. Determining the key mechanisms through which
exercise ameliorates disease-linked pathogenesis and signal
transduction dysfunction could optimise the beneficial role
of exercise in health promotion, minimise instances of im-
paired exercise adaptation and may facilitate the identification
of novel exercise-responsive drug targets.
In vivo experiments with human volunteers provide the
most integrated model with which to examine exercise-
induced health-promoting responses. Skeletal muscle biopsies
collected before and after acute exercise and/or exercise train-
ing programmes provide valuable observational insight into
associations between in vivo health benefits and specific
exercise-mediated changes in skeletal muscle gene expres-
sion, protein content and signal transduction pathways. For
example, the glucoregulatory and insulin-sensitising effects
of exercise have been associated with changes in skeletal mus-
cle expression and activity of several proteins, such as glucose
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transporter 4 (GLUT4) [11, 49, 102]. However, to confirm the
mechanistic importance of specific changes in skeletal muscle
in the resultant exercise-mediated health benefits, further ex-
periments (such as gain and loss of function) are required. The
unethical nature of such experiments in human participants, as
well as feasibility and practicality considerations, preclude the
ability to study individual molecular mechanisms of exercise
in isolation, in vivo in humans. Accordingly, a prime chal-
lenge for researchers working to understand the role of exer-
cise in the prevention and treatment of disease is to develop
and optimise experimental models that resemble elements of
exercise physiology in a more reductionist approach. In vitro
experimental models whereby skeletal muscle cells derived
from immortalised cell lines (e.g. C2C12 and L6) or isolated
from human or rodent skeletal muscle samples are exposed to
various skeletal muscle-specific exercise-like treatments
(shortened to ‘exercise-like treatments’ hereafter) such as elec-
trical pulse stimulation (EPS) or pharmacological compounds
have proved useful in this regard. Such ‘exercise in a dish’
approaches allow investigations into the cellular effects of
individual aspects of exercise physiology, such as skeletal
muscle contraction or activation of exercise-responsive signal-
ling pathways, directly upon the skeletal muscle cells, as well
as exercise-mediated cross-talk between different cell types.
Accordingly, the purpose of this review is to provide the ra-
tionale, potential application and evaluation of several models
that have been used to replicate and examine exercise-like
effects in vitro.
Criteria of an in vitro skeletal muscle-specific
exercise-like model
Models aiming to replicate skeletal muscle-specific aspects of
exercise in vitro must be validated against the complex range
of in vivo exercise-mediated changes. The exact mechanisms
of exercise-induced responses are not fully understood and
will vary depending on the exercise stimulus (modality, inten-
sity, duration) and whether such stimulus is performed acutely
or as part of a training regime [50]. That said, some aspects
apply universally to skeletal muscle contraction, and these will
be used for the purpose of evaluation of each exercise-like
treatment discussed within this review. Specifically, exercise
induces muscle contraction through increased intracellular
calcium ion (Ca2+) concentrations. Subsequent contractile ac-
tivity during exercise elicits multiple intracellular perturba-
tions within the contracting muscle, including decreased aden-
osine triphosphate (ATP) and phosphocreatine (PCr) content,
increased adenosine monophosphate (AMP) to ATP ratio and
increased free radical production, as well as other metabolic
and mechanical stresses [46]. Consequently, exercise in vivo
induces a cascade of transcriptional (e.g. peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC-1α),
GLUT4, enzyme and myokine mRNA expression), signalling
(e.g. activation of AMP-activated protein kinase (AMPK) and
Ca2+ activated kinases), proteomic (e.g. increased GLUT4
expression), metabolic (e.g. enhanced glucose uptake and
GLUT4 translocation [104, 105]) and morphological (e.g. hy-
pertrophy) changes within skeletal muscle (as reviewed pre-
viously [30]). Therefore, to be considered as an in vitro
exercise-like treatment, an experimental model must demon-
strate exercise-like effects with regard to the aforementioned
transcriptional, signalling and metabolic changes observed
in vivo. After such comparison, conclusions can be made
regarding the extent to which a model can resemble exercise.
In the following sections, we provide an outline of in vitro
models that have been applied to skeletal muscle myotubes in
conventional 2D cell culture models within the context of
exercise, including a comparison of the effects of each
in vitro exercise-like treatment to several exercise-induced
responses common to multiple in vivo exercise stimuli. See
Table 1 and Fig. 1 for summaries of this narrative. Please note
that for reasons further discussed within the limitations section
below, we have not directly compared each model to specific
types of exercise (e.g. endurance vs. resistance).
Electrical pulse stimulation
Background Skeletal muscle contraction that occurs during
exercise induces multiple disturbances in intracellular homeo-
stasis and subsequently activates multiple contraction-
mediated signalling pathways. Therefore, models that induce
skeletal muscle contraction, and subsequent activation of
contraction-mediated signalling pathways, provide perhaps
the most obvious option when trying to resemble exercise
in vitro. Electrical pulse stimulation (EPS) is an in vitro model
of skeletal muscle contraction that has been used for this pur-
pose. The application of EPS to skeletal muscle myotubes
derived from cell lines (e.g. C2C12 and L6 cells) and cultured
primary skeletal muscle cells has proved to be a major tool for
studying contraction-induced adaptations, and a comprehen-
sive overview has recently been published by Nikolić and
colleagues [86].
ApplicationsWhile the use of EPS dates back to the 1970s, its
specific use as an exercise-like treatment in vitro is a more
recent development. In particular, EPS has been applied to
study contraction-mediated changes in skeletal muscle signal
transduction [37, 83], metabolism [67, 85], myokine
regulation/release [99, 100, 112] and morphology [119].
Additionally, contraction-mediated cross-talk between skele-
tal muscle cells and other cell types (e.g. pancreatic beta cells
[5, 18], hepatocytes [33], monocytes [78], endothelial cells
[126]) and donor-specific adaptations [15, 34, 48] have been
addressed using EPS.
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Comparison to in vivo exercise Many studies have now dem-
onstrated that EPS induces visible contraction and elicits sev-
eral exercise-like effects. Similar to in vivo exercise, EPS-
induced responses depend upon the EPS stimulus (as
discussed by Nikolić et al. [86]). For example, short-term,
high-frequency stimulation has been proposed as a model of
acute high-intensity exercise as it induces exercise-like upreg-
ulation of glucose uptake [2, 85] and lactate production, de-
creased ATP and PCr content [85] and the activation of
contraction-related signalling pathways [75]. In contrast,
chronic low-frequency stimulation has been used to resemble
changes seen following exercise training given its exercise-
like effects upon activation of exercise-mediated signal trans-
duction (e.g. PGC-1α mRNA expression [99], AMPK [37,
67, 83], mitogen-activated protein kinase (MAPK), Ca2+ tran-
sients [37, 120]), stimulation of beneficial metabolic effects
(e.g. enhanced glucose uptake and oxidation, and insulin sen-
sitivity [67, 85] and increased mitochondrial content [85]),
myokine expression and release [7, 67, 99, 100, 112, 123]
and morphological changes (e.g. sarcomeric structure forma-
tion [37, 67] and myotube hypertrophy [119]). Such EPS-
induced sarcomeric structure formation reportedly relies upon
calpain-mediated proteolysis [37]. EPS has also been demon-
strated to increase lactate production, reduce intracellular gly-
cogen content [68] and protect against lipid-induced insulin
resistance [84]. However, some key changes seen following
exercise in vivo have not been reproduced in vitro. For exam-
ple, GLUT4 mRNA and protein expression and fatty acid
oxidation are increased following exercise in vivo, but these
effects have not been consistently demonstrated following
EPS. Additionally, whilst GLUT4 translocation, a key process
which contributes to the glucoregulatory effects of exercise
Table 1 A comparison between the in vivo effects of exercise and the in vitro effects of electrical pulse stimulation (EPS) and pharmacological
compounds on skeletal muscle cells
In vivo exercise effects EPS AICAR Caffeine Forskolin alone Ionomycin alone PFI
Intracellular perturbations ↑ Ca2+ transients ✓ ? ✓ ? ✓ ?
↓ ATP content ✓ × ? ? × ?
↓ PCr content ✓ ? ? ? × ?
↓ Glycogen content ✓ ? ? ? ? ?
↑ Lactate production ✓ × ? ? ? ×
Gene expression ↑ PGC-1α ✓ ✓× ✓ ✓ ✓ ✓
↑ GLUT 4 × ? ✓ ? ? ?
↑ IL-6 ✓ ✓ ? × ✓ ✓
↑ PDK4 ✓ × ✓ ? × ?
↑ CS ✓ ? ✓ ? ✓ ×
Pathway activation ↑ AMPK ✓ ✓ ✓× × ? ✓
↑ CaMKII ✓ ? ✓ ? ? ?
↑ MAPK × ✓× ? ? ? ?
↑ ACC ✓ ✓ ? × ? ?
↑ Akt ✓ × ? ? ? ?
↑ AS160 × × ? ? ✓ ?
Protein ↑ GLUT4 × ✓ ✓ ? ? ?
↑ Akt × × ? ? ? ?
Metabolism ↑ Glucose uptake and oxidation ✓ ✓ ✓× ? ✓ ×
↑ Fatty acid uptake and oxidation ✓× ✓ ✓ ? ? ✓
↑ Insulin responsiveness ✓ ✓ × ? ? ✓
↑ GLUT4 translocation ✓× ✓ ? ? ✓ ?
↑ Mitochondrial content ✓ ✓ ✓× ? ? ✓
↑ Mitochondrial function ? × ✓ ? ? ?
Myokine secretion ↑ IL-6 ✓ ✓ ? ? ? ?
Morphology and structure ↑ Hypertrophy ✓ × ? ? ? ?
↑ Sarcomere assembly ✓ ? ? ? ? ?
References are provided within the text of the relevant section
↑ indicates values increase following in vivo exercise, ↓ indicates values decrease following in vivo exercise, ✓ indicates the same direction of change
induced by exercise-like treatment compared to in vivo exercise, × indicates different direction of change induced by exercise-like treatment compared to
in vivo exercise, ✓ × indicates contradictory findings, ? indicates evidence lacking regarding the effect of exercise-like treatment
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in vivo, has been demonstrated in C2C12 myotubes [52, 68,
83], such effects have not yet been reported in human primary
muscle cell-based EPS models. Additionally, whilst C2C12
cells are responsive to EPS in regard to contractility, primary
human myotubes reportedly vary in their contractility depend-
ing on culture conditions and cell donor meaning that the
degree to which EPS induces exercise-like contraction can
be variable. The aforementioned discrepancies in results are
likely, at least in part, attributable to variability in EPS param-
eters used (as detailed previously [86]).
Technical considerations While EPS provides a useful tool
with which several key aspects of in vivo exercise can be
induced in vitro, several key technical considerations must
be acknowledged. Firstly, as discussed above, EPS-induced
contraction activates multiple signalling pathways.
Therefore, if the aim is to focus on a specific signalling path-
way, alternative methods (such as pharmacological com-
pounds discussed below) are required. Secondly, EPS can be
applied using commercial (e.g. C-Pace IonOptix generators)
or home-made systems. Commercially available systems are
perhaps the more convenient option, but lack of tracking ca-
pabilities mean it is difficult to determine/confirm whether
EPS parameters (e.g. frequency and voltage) are being consis-
tently applied during the experiment. Conversely, while track-
ing is possible with home-made systems, such setups likely
require expertise in electrical engineering [86].
Regarding protocol selection, whilst experimental data
supports the use of two distinct protocols to resemble acute
(i.e. short-term high-frequency stimulation) vs. chronic (i.e.
long-term low-frequency stimulation) exercise-like stimula-
tion [85, 86], direct comparison of specific EPS protocols to
different in vivo exercise programmes (e.g. aerobic vs. resis-
tance vs. interval exercise) is more difficult. By altering the
EPS parameters (e.g. duration, frequency, pulse trains vs. sin-
gle pulses, etc.), attempts have been made to resemble these
different types of exercise in vitro. Whilst different EPS
models do evoke different responses that may align a particu-
lar EPS protocol with a particular type of exercise, any single
EPS model can induce both similarities and differences to
both endurance and resistance exercise (e.g. [18]).
Therefore, it is perhaps best to consider EPS as a generalised
skeletal muscle contraction model that can be applied acutely
or chronically, rather than any specific type of exercise.
One consequence of the aforementioned attempts to resem-
ble different types of exercise is the clear inconsistency in EPS
Exercise
AMPK
Ca2+
Caffeine AICAR
CaMKII
EPS
Exercise-like response?
PFI
ZMP
AMP:ATP
cAMP, PKA
In vivo exercise EPS AICAR Caffeine PFI
Enhanced glucose metabolism
Enhanced lipid metabolism
Myokine regulation and release
Morphological changes
Fig. 1 Proposed experimental models to examine skeletal muscle-
specific exercise-like effects in vitro. Exercise in vivo (highlighted or-
ange) potently activates a range of changes within skeletal muscle that
contribute to the well-documented improvement of human health.
Exercise-like treatments (highlighted red) elicit several intracellular per-
turbations (highlighted purple) and activate several exercise-responsive
signalling pathways (highlighted green), and as discussed within the text,
consequently induce different exercise-like functional and metabolic
responses (highlighted blue) in skeletal muscle myotubes. References
are provided within the text of the relevant section. ✓ indicates the same
direction of change induced by exercise-like treatment compared to
in vivo exercise; × indicates different direction of change induced by
exercise-like treatment compared to in vivo exercise; ✓× indicates con-
tradictory findings; ? indicates evidence lacking regarding the effect of
exercise-like treatment
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parameters (duration, voltage, pulse duration and frequency)
used in published studies. Inevitably, discrepancies in EPS-
induced effects across studies are also evident. This is partic-
ularly true in studies performed on C2C12 and other rodent
models, with protocols rarely used in more than 1–2 publica-
tions, resulting in 40+ different protocol combinations (as
summarised by Nikolić et al. [86]). That said, some consisten-
cy can be seen with recent human EPS models with several
studies setting their EPS parameters as follows: 1 Hz, 2 ms,
11.5 V for 2–24 h [39–41, 58, 67, 100, 101]. This protocol has
also recently been applied to C2C12 cells [33].
As discussed by Nikolić and colleagues [86], correct care
and cleaning of carbon electrodes after each use are vital to
prevent chemicals leaching from the electrodes into the media
and inducing effects unrelated to the stimulus itself and/or
compromising cell viability. This is particularly important
when studying conditioned media-mediated effects within
cross-talk experiments. To do so, the following procedure
can be used: (1) rinse electrodes with distilled water, (2) soak
electrodes in distilled water for 2 days (refreshing water after
24 h), (3) disinfect electrodes with 70% ethanol, and (4) posi-
tion electrodes under UV lamp in tissue culture hood.
Following these procedures after each use should prevent
any issues developing as a result of incorrect care of the EPS
electrodes. Nevertheless, measurement of lactate dehydroge-
nase (LDH) and/or creatine kinase activity in the supernatant
should be completed to confirm that cell viability is not being
compromised by incorrect electrode cleaning procedures and/
or an unsuitable EPS protocol [67, 83, 85]. Similarly, in all
applications, the no EPS (control) condition should involve
placement of electrodes as in the EPS condition, but without
power. The addition of no cell/no EPS and no cell/EPS control
conditions are worthwhile additions to exclude any non-
specific effects that may result from factors leaching from
the EPS electrodes rather than factors secreted by skeletal
muscle myotubes [86].
Pharmacological compounds
Several compounds have been used in vitro to investigate the
molecular regulation of exercise-induced skeletal muscle ad-
aptations. Such compounds are primarily used based on their
ability to activate specific exercise-like signalling ormetabolic
conditions that occur within exercising skeletal muscle. These
compounds include 5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside (AICAR; an AMPK activator), caffeine (a
Ca2+ ionophore), ionomycin (a Ca2+ ionophore) and forskolin
(a protein kinase A (PKA) activator), and on occasion a
combination/cocktail of these. Below, we provide the ratio-
nale behind the use of each of these compounds, with the
specific protocol parameters used in the cited studies
summarised in Table 2.
AICAR
Background AMPK, a heterotrimeric protein complex, is a
master regulator of energy metabolism in skeletal muscle
[45]. Exercise potently activates the AMPK pathway within
skeletal muscle due to contraction-mediated increases in the
intracellular AMP/ATP and adenosine diphosphate (ADP)/
ATP ratios [45, 47]. This exercise-induced activation of
AMPK contributes to several exercise-mediated changes in
skeletal muscle metabolism, such as enhanced substrate up-
take and oxidation [47, 62]. Therefore, compounds that acti-
vate AMPK in skeletal muscle myotubes have been proposed
as tools to study the importance of exercise-like activation of
AMPK in the subsequent regulation of skeletal muscle metab-
olism. In particular, AICAR, which activates AMPK through
its role as an AMP mimetic, has frequently been used for this
purpose. Once transported into cells, AICAR is converted to
5-aminoimidazole -4 -carboxamide-1-β -D- r ibosy l
monophosphate (ZMP; an AMP analogue), and subsequently
results in AMPK activation [21].
ApplicationsWhilst AICAR is not always specifically used as
an ‘exercise-like treatment’, AICAR has commonly been used
as an AMPK activator within the context of exercise physiol-
ogy. For example, AICAR applied to C2C12 and L6
myotubes to study signalling pathways [8, 27, 31, 56, 79,
88, 111], metabolism [17, 51, 117], myokine release [114]
and protection against palmitate [108, 124] that may be regu-
lated by exercise-like AMPK activation. That said, studies
have also used AICAR with the stated intention to induce
‘exercise signals’ [79], to serve as an ‘exercise-mimetic pre-
cursor’ [90, 110] and to generate ‘trained’ cells [94] to study
exercise-related signalling [90, 91], myokine release [110] and
cross-talk [94]. AICAR has also been applied to primary hu-
man myotubes to investigate donor-specific responses to
AMPK activation, such as lean vs. obese [10], sedentary vs.
obese vs. T2DM vs. athletes [22] and healthy vs. T2DM [61,
82]. For example, different responses between donors have
been shown, with AICAR increasing AMPK activation in
lean but not T2DMmyotubes [61]. Conversely, similar effects
between donors have also been reported with regard to the
AICAR-induced enhancement of glucose uptake [77].
Comparison to in vivo exercise Whilst AICAR does not in-
duce skeletal muscle contraction, AICAR administration to
skeletal muscle myotubes induces several exercise-like effects
in vitro. In C2C12 or L6 cells, AICAR has been shown to
increase mRNA expression levels of PGC-1α [69, 88, 111]
and interleukin (IL)-6 [121]. Unsurprisingly, AICAR also ro-
bustly activates the AMPK-related pathway in C2C12 [31, 56,
76, 94, 109, 110, 115, 117, 121], L6 [43, 60, 90, 91, 98] and
primary human myotubes [22, 61], with only one study lack-
ing this effect [98]. Similarly, acetyl-CoA carboxylase (ACC)
Pflugers Arch - Eur J Physiol
Table 2 A summary of the protocol characteristics of in vitro pharmacological models used to examine exercise-like skeletal muscle contraction and/or
signalling
Model Cell type Purpose for application Duration Concentration References
AICAR C2C12 myotubes Exercise-like treatment 1–24 h 0.5 mM [110]
Exercise-like treatment 6 h 2 mM [79]
Exercise-like treatment 120 h 0.25 mM [94]
AMPK activator 2 min–2 h 0.5 mM [56]
AMPK activator 30 min 0.5–2 mM [76]
AMPK activator 30 min–2 h 0.1–2 mM [117]
AMPK activator 1–24 h 0.1–1 mM [121]
AMPK activator 1–24 h 0.1–2 mM [31]
AMPK activator 3 h 0.1–10 mM [51]
AMPK activator 3 h 0.25 mM [115]
AMPK activator 3–18 h 1 mM [114]
AMPK activator 3–24 h 0.5–2 mM [109]
AMPK activator 3–36 h 0.25–2 mM [111]
AMPK activator 6–24 h 1 mM [88]
AMPK activator 16 h 2 mM [32, 108]
AMPK activator 18 h 2 mM [124]
AMPK activator 24 h 0.25–1 mM [27]
L6 myotubes Exercise-like treatment 15–60 min 2 mM [6]
Exercise-like treatment 5 h 0.2–2 mM [98]
Exercise-like treatment 3 h/day for 5 days 1 mM [91]
AMPK activator 40 min 0.01–0.75 mM [17]
AMPK activator 40 min 0.05 mM [107]
AMPK activator 40 min 1 mM [8]
AMPK activator 45 min 1 mM [43]
AMPK activator 2 h 2 mM [66]
AMPK activator 16 h 1 mM [69]
AMPK activator 1–5 h for 1–6 d 1 mM [60]
AMPK activator 5 d 1 mM [90]
Human myotubes Exercise-like treatment 20 min 2 mM [77]
Exercise-like treatment 5 h 0.2 mM [98]
Exercise-like treatment 8 h–5 days 0.5 mM [22]
Exercise-like treatment 48 h 1 mM [64]
AMPK activator 30 min 1 mM [36]
AMPK activator 1–16 h 2 mM [10]
AMPK activator 1–24 h 0.1–1 mM [121]
AMPK activator 6 h or 8 days 0.1–2 mM [82]
AMPK activator 16 h 0.5 mM [61]
Caffeine C2C12 myotubes Exercise-like treatment 6 h 5 mM [79]
Ca2+ ionophore 2 min 1–20 mM [35]
Ca2+ ionophore 1–24 h 0.05–0.1 mM [113]
Ca2+ ionophore 3 h 0.5–10 mM [115]
L6 myotubes Exercise-like treatment 1–3 h 5 mM [6]
Exercise-like treatment 3 h/d for 5 days 5 mM [91]
Exercise-like treatment 5 h/d for 5 days 5 mM [89, 90]
Human myotubes Exercise-like treatment 3–24 h 2.5–20 mM [87]
Exercise-like treatment 48 h 3 mM [64]
Forskolin C2C12 myotubes Exercise-like treatment 3–18 h 1 μM [114]
PKA activator 30 min 20 μM [76]
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activation is a common finding across all cell types following
AICAR treatment (C2C12, [51, 76]; L6, [43, 60, 98]; human
[36]). Other exercise-like changes reported following AICAR
treatment include increased GLUT4 protein content [91, 107],
glucose uptake or oxidation [17, 66, 77, 98, 107], fatty acid
uptake or oxidation [60, 66, 82, 98], insulin responsiveness
[10, 124], GLUT4 translocation [43, 107], mitochondrial con-
tent [22] and IL-6 secretion [110]. However, in contrast to
some of these above-described findings, other studies demon-
strate a lack of effect of AICAR upon PGC-1α mRNA ex-
pression [6, 110], pyruvate dehydrogenase kinase 4 (PDK4)
mRNA expression [6, 64], FNDC5 (gene that encodes for
irisin) mRNA expression [110], as well as lack of effect upon
protein kinase B (Akt) protein content [56] and activation [31,
43], as well as Akt substrate 160 (AS160) activation [31, 43].
Findings regarding MAPK activation are currently inconsis-
tent, with increased activation [121] and no effect [51] report-
ed. Additionally, during skeletal muscle contraction, intracel-
lular ATP, PCr and glycogen levels decline. However, reports
have demonstrated that ATP content remains unchanged fol-
lowing AICAR exposure in C2C12 [117] and L6 [43]
myotubes, with no evidence of the effects upon PCr or glyco-
gen content. Similarly, in contrast to in vivo exercise, AICAR
treatment has been shown to have no effect upon myotube
lactate production [51] and appears to inhibit hypertrophy
[31] and mitochondrial function [117]. The wide range of
AICAR protocol parameters used (as detailed in Table 2), in-
cluding duration (e.g. 2 mins up to 8 days), concentration (e.g.
0.05 mM up to 10 mM) and single vs. repeated/intermittent
exposure, likely contribute to the aforementioned discrepant
findings and therefore should be considered when interpreting
results.
Caffeine
Background Skeletal muscle contraction results from
sustained elevations in intracellular Ca2+concentration,
Table 2 (continued)
Model Cell type Purpose for application Duration Concentration References
Human myotubes Exercise-like treatment 3–24 h 1 μM [87]
Exercise-like treatment 24 h 4 μM [9]
Ionomycin C2C12 myotubes Exercise-like treatment 3–18 h 1 μM [114]
Ca2+ ionophore 30 min 1 μM [55]
L6 myotubes Exercise-like treatment 10 min 1 μM [28]
Exercise-like treatment 1–5 h 1 μM [6]
Ca2+ ionophore 5 h/day for 5 days 1 μM [90]
Human myotubes Exercise-like treatment 3–24 h 1 μM [87]
Exercise-like treatment 6 h 1 μM [14]
Exercise-like treatment 24 h 0.5 μM [9]
Ca2+ ionophore 3–12 h 0.0005–0.002 μM [59]
PFI Human myotubes Exercise-like treatment 1 h/d for 3 d P (30 μM), F (4 μM), I (0.5 μM) [22–25, 65, 118]
Exercise-like treatment 3 d P (30 μM), F (2 μM), I (1.6 μM) [4]
A23187 C2C12 myotubes Exercise-like treatment 1 h 1 μM [38]
Ca2+ ionophore 3 h 10 μM [115]
Ca2+ ionophore 6 h 0.4 μM [3]
Ca2+ ionophore 9–24 h 0.1–1 μM [29]
L6 myotubes Exercise-like treatment 30 min–5 h 10 μM [54]
Ca2+ ionophore 3 h 1 μM [72]
Ca2+ ionophore 6 h 0.05–1 μM [44]
ex229 L6 myotubes AMPK activator 2 h 0.5–1 μM [66]
R419 C2C12 myotubes AMPK activator 2 h 0.2 μM [57]
SRT1720 C2C12 myotubes SIRT1 activator 1–24 h 2.5 μM [92]
GW501516 Human myotubes PPARδ activator 1–18 h 0.1 μM [63]
PPARδ activator 3 day 0.0001–0.05 μM [122]
H2O2 C2C12 myotubes Exercise-like treatment 6 h 1 mM [79]
L6 myotubes Exercise-like treatment 15–60 min 1 mM [6]
NaNO3 C2C12 myotubes Exercise-like treatment 1 d 25–500 μM [103]
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inducing several downstream effects including activation of
the Ca2+/calmodulin-dependent protein kinase II (CaMKII)
pathway. Ca2+ ionophores are compounds which increase in-
tracellular Ca2+ concentrations and thus have been used to
study the effects of exercise-like CaMKII pathway activation
in skeletal muscle myotubes. Caffeine triggers Ca2+ release
from the sarcoplasmic reticulum and increases intracellular
Ca2+ concentration in skeletal muscle [89] and is one com-
pound that has been used for this purpose.
Applications Caffeine treatment has been applied to skeletal
muscle myotubes as a Ca2+ ionophore, as well as with the
specific intent to provide an ‘exercise-like treatment’ [79],
mimic exercise activation [64, 87] or exercise signals [91]
and trigger exercise-like Ca2+ changes [90]. In this context,
caffeine has been used to examine exercise-regulated changes
in signal transduction and metabolism in L6 [6, 28, 89–91]
and C2C12 cells [79, 113]. To date, caffeine has been less
readily applied to primary human myotubes than other com-
pounds discussed in this review, and in the studies that have,
healthy donor myotubes are primarily used [64, 87].
Comparison to in vivo exercise Caffeine has been shown to
stimulate several exercise-like effects within skeletal muscle
myotubes. Unsurprisingly, caffeine consistently induces Ca2+
transients and thus can induce contraction [35, 89, 90, 115].
Caffeine has been shown to increase mRNA expression of
markers of mitochondrial biogenesis and oxidative metabo-
lism, such as PGC-1α [6, 87, 113], GLUT4 [87], PDK4 [6,
64, 87] and citrate synthase (CS) [6]. Protein abundance of
GLUT4 [91, 113] and mitochondrial enzyme [89] proteins, as
well as fatty acid uptake/oxidation [90] and mitochondrial
function [113], have been shown to be increased following
caffeine treatment, similar to exercise in vivo. Conversely,
some inconsistent effects have also been reported. For exam-
ple, AMPK activation has been shown to be increased [113,
115] and unchanged [90] following caffeine treatment.
Similarly, increased [113] and inhibited [35] glucose uptake
or oxidation and increased [89, 90] and unchanged [113] mi-
tochondrial content have also been reported following caffeine
treatment. Caffeine administration to primary human
myotubes has been shown to induce several responses differ-
ent to those seen following in vivo exercise, such as reduced
FNDC5 expression [87] and insulin responsiveness [35], with
the latter being a stark contrast to the insulin-sensitising effect
of exercise in vivo. Additionally, limited data exist regarding
the effects of caffeine on other exercise-responsive signalling
pathways, such as ACC, Akt, AS160 and MAPK activation,
intracellular content of high-energy phosphates (e.g. ATP and
PCr) and aspects of skeletal muscle metabolism (e.g. GLUT4
translocation), morphology and myokine secretion. Similar to
EPS and AICARmodels, variation in the exact protocols used
within caffeine-based models (as detailed in Table 2) with
regard to duration (e.g. 2 mins up to 48 h), concentration
(e.g. 0.05 mM up to 20 mM) and use of single vs. repeated/
intermittent pulses likely contribute to inconsistent results be-
tween studies.
Palmitate, forskolin and ionomycin (PFI)
Background Exercise enhances in vivo fat oxidation whilst
stimulating both Ca2+ and adrenergic (cyclic AMP (cAMP)
and PKA) signalling pathways within skeletal muscle. As
such, compounds that increase lipid oxidation in skeletal mus-
cle in vitro and activate one or both of these pathways provide
tools which can be used to delineate the role of the specific
pathway in exercise-mediated changes within skeletal muscle.
Palmitate (in low concentrations, increases lipid oxidative ca-
pacity of skeletal muscle myotubes without impairing insulin
sensitivity [118]), forskolin (raises intracellular cAMP and
activates PKA) and ionomycin (a Ca2+ ionophore) have been
used alone or in combination for this purpose.
Applications Of the compounds discussed within this review,
ionomycin/forskolin/PFI have the highest proportion of arti-
cles where it has been applied with the specific intention of
providing an exercise-like treatment in vitro, with terminology
used including ‘exercise mimetic signalling compounds’ [9],
‘exercise mimetic stimulation’ [24], ‘in vitro exercise model’
[25] or ‘exercise mimicking cocktail’ [65]. Ionomycin or
forskolin alone have been applied to C2C12 or L6 cells to
investigate skeletal muscle signalling [6, 76, 90], metabolism
[55, 90] or myokine release and expression [114]. Primary
applications of ionomycin or forskolin alone to primary hu-
man myotubes include investigations into intracellular signal-
ling and myokine release or expression [9, 14, 59, 87], with
myotubes primarily established from healthy donors. These
compounds have also frequently been used in combination
with palmitate as part of a lipolytic cocktail (palmitate,
forskolin, ionomycin or PFI). Within this context, PFI has
almost solely been applied to primary human myotubes to
investigate exercise-related signalling [4, 22, 65], metabolism
[22, 118] and myokine release/regulation [65]. Additionally,
most of these studies have worked to determine if donor-
specific responses exist, including sedentary vs. active vs.
obese vs. T2DM [22], healthy vs. T2DM [4, 65] and sedentary
vs. active vs. T2DM [24] comparisons. For example, lipid-
droplet protein perilipin 3 (PLIN3) content, which is associat-
ed with lipid metabolism in vivo, increases after both exercise
and PFI treatment [23]. Interestingly, the PFI-induced increase
in PLIN3 protein was greatest in sedentary donor myotubes,
with gradual increases in T2DMdonor myotubes and minimal
changes in active donor myotubes which almost exclusively
favour the expression of another perilipin protein, PLIN5,
following PFI treatment [24]. Additionally, differential
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myokine expression has been reported following PFI treat-
ment, with IL-8 increased vs. decreased in myotubes from
sedentary vs. active donors following PFI, respectively [25].
Comparison to in vivo exercise Forskolin alone demonstrates
few responses similar to exercise in vivo. Whilst forskolin-
induced upregulation of PGC-1α mRNA expression [87] is
similar to exercise in vivo, negative effect upon IL-6 and
FNDC5 mRNA expression [9] and a lack of effect upon
AMPK and ACC activation [76] suggest that forskolin alone
does not satisfactorily resemble enough aspects of in vivo
exercise. In contrast, ionomycin application to skeletal muscle
myotubes has been shown to increase PGC-1α [6, 87], IL-6
[9, 59] and CS [6] mRNA expression, Ca2+ transients [59, 90],
AS160 activation [28], glucose uptake and oxidation [55] and
GLUT4 translocation [28]. That said, evidence from
ionomycin only experiments have shown a lack of effect upon
ATP and PCr levels [90] and PDK4 mRNA expression levels
[6]. PFI has been primarily applied to primary human
myotubes, and several exercise-like effects have been shown.
Firstly, PFI treatment reportedly stimulates contraction of
myotubes [118], as well as increases in PGC-1α [65] and
IL-6 [25] mRNA expression, AMPK activation [22], insulin
responsiveness (at the level of glycogen storage [118]), fatty
acid uptake and oxidation [118] and mitochondrial content
[22, 118]. However, unlike exercise, PFI has been shown to
have no effect upon CS mRNA expression [118], glucose
uptake [118] and lactate production [118], as well as inducing
a reduction in FNDC5 mRNA expression [65]. The apparent
greater consistency of results between PFI-based studies
(compared to relative inconsistency within the other models
discussed) is likely attributable, at least in part, to the lower
number of protocol variations used across studies
(summarised in Table 2). That said, to date, the effects of
PFI upon several exercise-like responses, including GLUT4
mRNA expression, protein content and translocation, PDK4
mRNA expression, Ca2+ transients, intracellular ATP, PCr and
glycogen content as well as exercise-responsive signalling
cascades (such as activation of ACC, Akt, AS160 and
MAPK), have not been fully characterised.
Other pharmacological compounds
Theoretically, any compound that can stimulate exercise-like
responses at transcriptional, signalling and metabolic levels
may be a viable tool to investigate exercise-related adapta-
tions. A23187, a Ca2+ ionophore also known as calcimycin,
has been applied to C2C12 or L6 myotubes to increase intra-
cellular Ca2+ content [3, 29, 44, 72, 115], as well as with a
stated intention to serve as an exercise-like treatment [38, 54].
A23187 has been shown to increase IL-6 mRNA expression
[3], myosin heavy chain (MHC)-I expression [29], activate
AMPK [115], increase hexokinase II expression [44], LDH
activity [54] and increase p38 phosphorylation [72]. However,
further studies establishing the effects of A23187 on primary
human myotubes are required.
Improved glucose uptake and fatty acid oxidation have
been reported in L6 myotubes following treatment with
ex229 (an AMPK activator) [66]. Similarly, AMPK activator,
R419, reportedly increased glucose uptake and GLUT4
promotor activity in C2C12 myotubes [57]. SRT170 provides
another compound with which AMPK activation and mito-
chondrial biogenesis can be upregulated in C2C12 myotubes
[92]. Peroxisome proliferator-activated receptor (PPAR) β/δ
levels increase in skeletal muscle during exercise and are cen-
tral to exercise-mediated metabolic regulation. PPAR ago-
nists, such as GW501516, have also been used to study the
effects of exercise-like activation of PPAR pathways in prima-
ry human myotubes. GW501516 elicits AMPK and ACC ac-
tivation, enhanced glucose uptake, fatty acid uptake and oxi-
dation, as well as upregulation of lipid metabolism-related
genes (e.g. PDK4) [63, 122].
To induce exercise-like reactive oxygen species (ROS) pro-
duction, hydrogen peroxide (H2O2) has been applied to
C2C12 and L6 myotubes, demonstrating exercise-like effects
with regard to increased mRNA expression of PGC-1α, CS
and PDK4 [6] and genes involved in ribosome biogenesis
[79]. Finally, nitrate (NaNO3) treatment of C2C12 myotubes
has been shown to increase mRNA expression of PGC-1α,
PPARδ, MYH7 and MYH2, as well as induce the release of
suspected muscle-derived factors into conditioned media (e.g.
irisin and beta-aminoisobutyric acid). Such observations have
led authors to conclude that NaNO3 induces responses that
mimic exercise [103].
All of the above-described approaches to induce exercise-
like effects in vitro have their advantages. However, several
science gaps urgently warrant exploration. Namely, the effects
of these different modalities on functional measures like glu-
cose uptake, myokine secretion and oxygen consumption
should be determined in primary human myotubes. Such fu-
ture work would better characterise the response to each treat-
ment and allow for a thorough comparison to corresponding
in vivo measurements of the same functional outcomes.
Limitations and future developments
applicable to all approaches
Each of the experimental models discussed has their own spe-
cific limitations. Additionally, there are several limitations that
apply to most or all of the aforementioned models. These are
discussed below along with suggestions for improving meth-
odological clarity and improving the physiological nature of
such models. See Fig. 2 for a summary of this discussion.
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The absence of aspects of in vivo exercise physiology A myr-
iad of physiological changes occur during exercise in vivo,
including increased blood flow and alterations in circulating
substrates and molecules (e.g. hormones), microenvironment
(e.g. local hypoxia, temperature) and autonomic nervous sys-
tem [46]. The absence of these exercise-mediated stimuli as
well as a lack of cell-extracellular matrix interaction and me-
chanical load [55] should be acknowledged when making
conclusions using data derived from these in vitro models.
The lack of flow across skeletal muscle cells during culture/
exercise-like treatment can result in a static accumulation of
secreted factors, which is particularly relevant within cross-
talk experiments where final concentrations of secreted factors
can become supraphysiological. Additionally, substrate up-
take is regulated by a balance of delivery, transport and me-
tabolism [105], and during exercise in vivo the balance be-
tween carbohydrate and fatty acid oxidation shifts depending
on exercise duration and intensity. However, the lack of flow
across skeletal muscle cells (i.e. no change in substrate deliv-
ery) and the use of only one energy source in most studies
during exercise-like treatment mean current models do not
account for these important aspects of in vivo exercise phys-
iology. Introduction of a perifusion system whereby culture
media can be continuously circulated would prevent static
accumulation of secreted factors and allow alterations in the
presence of exercise-responsive hormones and/or fuel source
provision during treatment to be made. Inclusion of mechan-
ical stretching to resemble exercise-like mechanical load may
be a useful future addition because it has been shown to acti-
vate AMPK [81, 106], Akt [106, 116], CaMKII [55, 106], and
p70S6 kinase [80, 81]-related signalling pathways, and to in-
crease glucose uptake [55], GLUT4 translocation [106] and
myotube hypertrophy [116]. It should be noted that mechan-
ical stretching is not discussed fully in this review because it
requires flexible and patterned culture membranes within
stretch chambers that are not applicable to conventional 2D
culture, the focus of this review. Finally, it should be noted that
adaptations to repeated exercise during a period of training
result from transient activation followed by inactivation of
exercise-related transcriptional and signalling responses with-
in skeletal muscle [30]. In contrast, exercise-like treatment
models where the stimulus is often applied chronically over
many hours or days may not accurately reflect the episodic
nature of in vivo exercise and thus may explain some of the
discordances in effects seen following in vivo exercise vs.
exercise-like treatment in vitro. That said, efforts to resemble
the episodic nature of in vivo exercise within exercise-like
treatment models have been made, with EPS (e.g. [16]),
AICAR [60, 91], caffeine [89–91] and PFI [22–25, 65, 118]
applied through daily pulses interspersed by periods of ‘rest’.
Overall, a combination of these exercise-like treatments with
other techniques, such as hypoxic cell culture conditions
(which has recently been combined with EPS [39]), mechan-
ical stretching, co-culturing with other cell types and
perifusion systems, could make each model more representa-
tive of in vivo exercise physiology.
Perifusion system
Mechanical stretching system
Hypoxic cell culture
Provide full protocol details along 
with results of supporting pilot 
experiments within 
publications/supplementary material
Serial sample harvests following 
treatment cessation 
Incorporate relevant exercise-
responsive measures
Acknowledge the cell source and 
culture conditions to determine 
whether the treatment has been used 
in the context of health or disease
Identify and clearly state which 
aspect of exercise is being targeted
Possible improvement
Co-culturing with other cell types
The absence of aspects of in vivo
exercise physiology
Difficulty comparing between and 
replicating studies due to cell culture 
and/or exercise-like treatment 
protocols varying greatly
Lack of a time course of the post-
treatment changes
The exercise-like effect of each 
model is not fully characterised
Experiments conducted under 
abnormal/disease-like conditions 
without a normal/healthy comparator 
condition
Choice of terminology can be 
inappropriate and/or inconsistent
Limitation
Fig. 2 Summary of limitations
and possible future improvements
applicable to all in vitro skeletal
muscle-specific exercise-like
models. Several limitations inher-
ent to all models discussed have
been identified from existing lit-
erature (highlighted red), and
possible improvements have been
suggested (highlighted green).
See text for thorough discussion
of each limitation/improvement
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Difficulty comparing between and replicating studies
Differences in routine cell culture procedures and ‘exercise
treatment’ protocols used can make direct comparisons be-
tween and replication of studies difficult. For example, media
constituents (e.g. serum and glucose concentration), days of
differentiation, cell seeding densities, the presence of plate
coating, media change frequency, cell passage and sample
harvesting time could all feasibly influence how cells respond
to each exercise-like treatment. Equally, differences in param-
eters used in EPS-based (duration, frequency, pulse duration;
as detailed previously [86]) and compound-based (duration,
concentration, single vs. repeated/intermittent pulses; as
summarised in Table 2) experiments all likely contribute to
different responses. Whilst such differences in protocols
across studies is not a limitation of the models per se, these
details are often omitted and/or vary greatly across studies,
highlighting the need for caution before making direct com-
parisons across studies. That said, there is one exception: pro-
tocol parameter selection in the existing literature that has used
PFI as a stimulus is admirably consistent. Additionally, the
selection of the specific protocol parameters used in published
work, such as concentration (compound-based methods), du-
ration (all methods), frequency and voltage (EPS), have very
likely been informed by dose-response and/or time course
pilot experiments. The results of such pilot experiments, along
with specific protocol information and video footage demon-
strating myotube contractility, should be presented in publica-
tions or at the very least within the supplementary material.
This would improve consistency and reduce systematic error
in repeated work and would facilitate fairer between-study
comparisons and therefore improve the quality of data
interpretations.
Lack of a time course of the post-treatment changes As de-
termined by serial skeletal muscle biopsies following exercise
cessation, the evidence demonstrates a time-dependent effect
upon exercise-regulated signalling events within skeletal mus-
cle in vivo (e.g. [19, 30, 70, 71]). It is likely that time-
dependent activation also likely occurs following cessation
of exercise-like treatment in vitro. Indeed, serial sample har-
vests have demonstrated that PFI-induced changes in IL-6
mRNA expression [25], and EPS-induced GLUT4 recycling
[83], IL-6 mRNA expression [7], PPARδ mRNA expression
[93] and myotube hypertrophy [119] exhibit significant time
effects over the period following treatment cessation.
However, most studies harvest samples at a single time point
following treatment cessation, which can vary across studies,
meaning the time-course for changes following each of these
treatments is not well characterised. Therefore, time-course
studies incorporating serial sample harvests following treat-
ment cessation are required to ensure changes with different
kinetics (e.g. rapid, transient or delayed) are not missed and
thus allow full characterisation of responses to each model.
The exercise-like effect of each model is not fully
characterised As addressed in each section above and clearly
demonstrated by the question marks in Table 1, several func-
tional and molecular responses to in vivo exercise have not
been similarly examined nor characterised in each in vitro
model. For example, whilst EPS- and AICAR-based models
are fairly well characterised, large gaps remain regarding the
effects of the other pharmacological compounds on key
exercise-responsive intracellular signalling and metabolic
changes. Without such information, a full comparison of each
in vitro model to in vivo exercise is not possible. Therefore, to
fully characterise the extent to which each model resembles
in vivo exercise, future studies should incorporate relevant
exercise-responsive measures (referred to as positive controls
in the next section) to address the gaps highlighted in Table 1.
Experiments conducted under abnormal/disease-like condi-
tions without a normal/healthy comparator condition While
cell lines offer consistent, robust and predictable cell growth
patterns, excessive culture durations and handling make cell
lines prone to deviate from normal function. Additionally,
donor characteristics (which are to an extent retained in cul-
tured myotubes [1]), biopsy site (which can influence cell
proliferation and differentiation rates [12] and fibre type het-
erogeneity/distribution) and reason for biopsy sample collec-
tion (including surgical biopsies, which can introduce con-
founding effects of non-specified chronic disease) could all
influence how primary human myotubes respond to each
treatment. Additionally, culture media glucose concentration
prior to and during these exercise-like treatments varies from 5
to 25 mM. Since exposure to high glucose concentrations (i.e.
25 mM) can induce insulin resistance in skeletal muscle
myotubes [42, 53, 125], studies that have cultured myotubes
in hyperglycaemic conditions prior to and during the respec-
tive exercise-like treatment (for example, EPS-based [7, 26,
52, 75, 93, 126], AICAR-based [88, 94, 110] and caffeine-
based [113, 115] models) may have been conducted under
disease-inducing conditions. Therefore, acknowledging
whether the effects of these exercise-like treatments have been
investigated in the context of health (e.g. insulin responsive)
or disease (e.g. insulin resistant) is important for increasing the
accuracy of data interpretation and subsequent impact.
Choice of terminology As mentioned in each section, the
choice of terminology used when describing each treatment
varies greatly across studies and may not always be fully ap-
propriate. For example, terms such as exercise mimetic or
exercise treatment inherently imply that the tool copies all
aspects of exercise, which, as discussed throughout, is not
the case. Equally, whilst altering the specific protocol param-
eters (EPS—duration, frequency, pulse duration; pharmaco-
logical compound—duration, concentration, single vs.
repeated/intermittent pulses) can evoke different responses
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that may align a particular protocol with a particular type of
exercise, any one protocol can induce both similarities and
differences to both endurance and resistance exercise.
Moreover, an apparent focus of compound-based literature
(particularly caffeine and PFI) upon endurance exercise-like
responses, and a relative dearth of information addressing the
potential effects upon resistance exercise-like responses pre-
clude the ability to exclude the possibility that a single proto-
col does indeed evoke a hybrid of endurance-like and
resistance-like effects in vitro. Therefore, whilst the notion
of designing distinct endurance exercise-like or resistance
exercise-like treatments is an appealing one, current evidence
does not permit researchers to confidently state that protocol A
fully resembles endurance exercise, and protocol B fully re-
sembles resistance exercise. Such considerations strongly in-
fluenced our decision to not directly compare each experimen-
tal model to specific types of exercise and clearly highlight the
need for careful choice of terminology when referring to each
treatment. For example, terminology such as in vitro skeletal
muscle-specific exercise-like treatment (or shortened to ‘exer-
cise-like treatment’ as throughout this review) may provide a
more accurate and conservative description of this set of
models in general. Better still, stating whether the model is
being used to target skeletal muscle contraction or specific
exercise-responsive signalling pathways would improve con-
sistency between studies, as well as enhance the quality of
data interpretation.
Model selection and practical considerations
In vitro, muscle-specific exercise-like treatments enable us to
probe specific molecular mechanisms of exercise adaptations.
This is not otherwise possible using human exercise studies
alone. Each of these in vitro models induces several exercise-
like changes in skeletal muscle cells. This includes the en-
hancement of glucose metabolism and activation of several
exercise-responsive signalling pathways. Nevertheless, each
model has different advantages and careful consideration is
required before selecting a single model.
Research aim Firstly, the specific research aim should form the
basis of this decision. For example, if the aim is to investigate
skeletal muscle contraction per se and all signalling pathways
that contraction regulates, EPS may be preferable. In contrast,
if the aim is to target a single, specific exercise-responsive
signalling pathway (e.g. AMPK, cAMP/PKA, CaMKII, etc.)
to investigate downstream targets/metabolic outcomes, then
utilising the appropriate pharmacological agonist would likely
be more appropriate. The main target for each application is
summarised in Fig. 1. That said, as discussed above, these
compounds often activate multiple pathways and have
additional off-target effects. This must be considered when
designing protocols and interpreting results.
Equipment available EPS requires specialised equipment that
can be expensive and difficult to maintain, whereas the use of
pharmacological agonist compounds simply requires the ad-
dition of such compounds to cell culture media. Therefore, a
cost-benefit analysis of logistics, equipment, and finances
available must also be considered.
Controls When investigating the effects of each of these
exercise-like treatments, it is important to include measure-
ments that can be used to confirm the treatment has induced
some exercise-like effect. For example, assessment of muscle
contraction, glucose metabolism, exercise-related signalling
and myokine secretion provide appropriate positive controls
to determine the extent to which a model is able to resemble
aspects of in vivo exercise. In cross-talk experiments, addi-
tional controls whereby the exercise-like treatment is applied
to media without cells are also important. Implementation of
such controls in EPS-based models is recommended by
Nikolić et al. [86] and is discussed above. Within
compound-based experiments, such controls would involve
incubating the target cell in fresh (i.e. non-conditioned)
compound-containing media to investigate whether the com-
pound alone impacts the target cell. Such controls have been
implemented previously (e.g. [94]) and are vital to exclude the
possibility that observed effects result from the compound that
remains in the skeletal muscle cell conditioned media rather
than factors secreted from skeletal muscle cells.
Future applications
As discussed throughout, each model has been used to answer
different exercise-related questions. Because many research
questions remain, in vitro models will likely form a large
component of future research in this field. For example, appli-
cation of these models, where possible, to primary human
skeletal muscle myotubes as a more physiologically and ge-
netically relevant model of human health and disease [1]
would enhance the impact of findings gained. In particular,
the evidence demonstrates the preservation of metabolic phe-
notype in myotubes established from different donors (e.g.
healthy, obese, diabetic [1]), as well as following acute/
chronic exercise in vivo (e.g. improved lipid metabolism and
glucose metabolism) [13, 73] and surgery [48]. Therefore,
application of these in vitro exercise-like treatments to
myotubes derived from human donors of different disease
states and/or exercise statuses may prove most useful in the
identification of new molecular targets to prevent/treat dis-
ease. Similarly, application of these models to myotubes iso-
lated from individuals showing different adaptations to the
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same exercise stimulus (i.e. responders vs. non-responders)
will advance our understanding of inter-individual variability
in the response to exercise. Such an approach would contrib-
ute to reducing the occurrence of a non-response to exercise.
Conclusion
The application of EPS or various pharmacological com-
pounds to skeletal muscle myotubes provide distinct experi-
mental models able to induce some exercise-like effects
in vitro and therefore provide valuable high-throughput tools
to study the skeletal muscle cell biology of exercise-mediated
health benefits. By targeting muscle contraction (e.g. using
EPS) or exercise-related signalling pathways (e.g. AMPK or
CaMKII using pharmacological compounds), specific aspects
of muscle function and metabolism can be isolated using
in vitro approaches. Future optimisation to enhance the phys-
iological nature of these current in vitro models will further
enhance their impact within muscle biology research and thus
contribute to addressing key challenges in this field, such as
maximising the therapeutic potential of exercise and facilitat-
ing the identification of novel exercise-responsive drug
targets.
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